Unhealthy drug use ranges from use that risks health harms through severe drug use disorders. This narrative review addresses whether screening and brief intervention (SBI), efficacious for risky alcohol use, has efficacy for reducing other drug use and consequences. Brief intervention among those seeking help shows some promise. Screening tools have been validated though most are neither brief...

Bruneau, J 1,2 , Zang, G 1 , Abrahamowicz, M 3 , Jutras-Aswad, D 1,4 , Daniel, M 5 , Roy, E 6,7 . 1 Research Center, Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Québec, Canada. 2 Department of Family Medicine, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada. 3 Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montr...

core decompression (cd) of the femoral head is one of the effective treatments of avascular necrosis (avn), especially in the early stages of the disease. to investigate further the value of cd in treating the avn, this study was performed on patients with symptomatic avn with different etiologies who were treated with cd. this study was carried out on 25 patients (with the total number of 37 f...

Methods In this randomized trial (the Assessing Screening Plus brief Intervention’s Resulting Efficacy to stop drug use (ASPIRE) study) we tested the efficacy of a brief negotiated interview (BNI), and an adaptation of motivational interviewing (AMI), compared to no BI. Primary care patient participants had Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) drug specific scores ...

Material and methods We randomly assigned participants identified by screening with Alcohol Smoking and Substance Involvement Screening Test (ASSIST) drug specific scores of 2 or 3 (consistent with low risk drug use) to: no BI, a brief negotiated interview (BNI), or an adaptation of motivational interviewing (MOTIV). BNI was a 10-15 minute structured interview conducted by health educators. MOT...

Drug testing with traditional behavioral assays constitutes a major bottleneck in the development of novel therapies. PsychoGenics developed three comprehensive high-throughput systems, SmartCube(®), NeuroCube(®) and PhenoCube(®) systems, to increase the efficiency of the drug screening and phenotyping in rodents. These three systems capture different domains of behavior, namely, cognitive, mot...